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Abstract: Epigenetics refers to heritable traits that are not a consequence of DNA sequence. Three classes of
epigenetic regulation exist: DNA methylation, histone modiﬁcation, and noncoding RNA action. In the
cardiovascular system, epigenetic regulation affects development, differentiation, and disease propensity or
expression. Deﬁning the determinants of epigenetic regulation offers opportunities for novel strategies for
disease prevention and treatment.
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Epigenetics was ﬁrst deﬁned as the complex interplay be-
tween the genome and environmental factors that govern
cell and organ differentiation and development. At the
current time, this term refers to heritable traits that are
not a consequence of changes in DNA sequence. These
traits are the result of alterations in gene expression reg-
ulated by changes in DNA accessibility or chromatin
structure. Epigenetic modiﬁcations, or tags, that lead to
changes in DNA accessibility can be brought about by
DNA methylation, posttranslational modiﬁcation of his-
tone proteins, or noncoding RNA actions in the nucleus.
1
Epigenetic modiﬁcations can be affected by exogenous
factors and environmental exposures, providing a mecha-
nistic link between genes (or the genome) and environ-
ment (or the exposome) in deﬁning phenotype and offer-
ing an explanation for phenotypic differences between
monozygotic twins.
2 The ﬁeld of epigenetics is expanding
rapidly, with a number of ongoing international research
initiatives, including the Human Epigenome Project
3 and
the International Human Epigenome Consortium.
4 Grow-
ing evidence supports the view that epigenetic modiﬁca-
tions also contribute to the pathogenesis of cardiovascular
disease and the expression of cardiovascular pathopheno-
types.
CHROMATIN STRUCTURE
Chromatin comprises nuclear DNA associated with spe-
ciﬁc nuclear proteins. The DNA coils around histone pro-
teins forming nucleosomes; the nucleosome contains an
octomeric core of histone proteins (two H3-H4 histone
dimers and two H2A-H2B dimers) bound to a 147-base-
pair stretch of DNA. The H1 histone protein binds to the
internucleosomal DNA linker sequences. Chromatin struc-
ture is determined by nucleosome spacing and can be cate-
gorized as transcriptionally inactive, densely packed het-
erochromatin, or transcriptionally permissive, less densely
packed euchromatin.
5,6 The structure of chromatin and its
consequences for gene expression are regulated by bio-
chemical modiﬁcations both to DNA and to the amino-
terminal histone tails that extend from the nucleosome
into the nuclear lumen.
EPIGENETIC TAGS
DNA methylation
Covalent attachment of a methyl group to the C5 position
of cytosine comprises the principal epigenetic modiﬁca-
tion of DNA. This modiﬁcation occurs primarily in CpG
dinucleotide-containing regions, often in regulatory se-
quences that suppress gene expression. CpG methylation
is important for transcriptional repression of transposons
and repeat elements, for imprinting and X-chromosome
inactivation,
7 and for tissue-restricted gene expression dur-
ing development and differentiation.
8 Methylation of cy-
tosines not within CpG sequences can also occur and is
important for regulation of gene expression in embryonic
stem cells.
9
Address correspondence to Dr. Joseph Loscalzo, Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115-
2394, USA. E-mail: jloscalzo@partners.org.
Submitted September 12, 2013; Accepted December 10, 2013; Electronically published May 9, 2014.
© 2014 by the Pulmonary Vascular Research Institute. All rights reserved. 2045-8932/2014/0402-0004. $15.00.The presence of a methylated cytosine can repress
transcription by inhibiting the binding of transcription
factors or may promote the binding of other transcrip-
tional repressors, including histone-modifying proteins,
such as histone deacetylases (HDACs). Cytosine methyla-
tion at CpG dinucleotides is carried out by a family of
enzymes, the DNA methyltransferases (DNMTs), which
include the de novo methyltransferases DNMT3a and
DNMT3b, and by DNMT1, which recognizes and methylates
the nonmethylated daughter strand during DNA replica-
tion.
10 Base-pairing rules permit maintenance of recipro-
cal methylation during subsequent cycles of DNA replica-
tion, which, in turn, offers a mechanism for passing a
nongenetic trait from cell to cell. In this way, DNA meth-
ylation is considered a long-term, stable epigenetic trait.
Although demethylation is known to be an essential
process that occurs during certain stages of development,
the mechanism of DNA demethylation is less understood
than that of methylation. Demethylation may play an es-
sential role in modulating brain plasticity or transcrip-
tional responses to hormones, and targeted or global loss
of methylation has been associated with cancer, cardiovas-
cular disease, and other pathologies. Global decreases in
DNA methylation can be caused by suppression of DNMT1
methyl transferase. Recent evidence suggests that demeth-
ylation may occur by other enzymaticmechanisms that rely
on excision-repair mechanisms to replace methyl cytosine
with cytosine following deamination. These mechanisms
may promote global or targeted changes in methylation.
One possible pathway for demethylation involves oxidiza-
tion of methyl cytosines to hydroxymethyl cytosine by the
ten-eleven translocation (Tet) enzymes. Growing evidence
suggests that hydroxymethyl cytosine formation is an inter-
mediate stage in DNA demethylation possibly due to its
increased susceptibility to deamination.
11 At this time, it is
unclear whether 5 hydroxymethyl cytosine may have other
essential functions as an epigenetic marker capable of reg-
ulating gene expression and chromatin structure; however,
the function of the Tet proteins appears to be important for
replication-independent DNA demethylation.
12
Histone modiﬁcation
Histones undergo a variety of posttranslational modiﬁca-
tions, including acetylation, methylation, phosphorylation,
andubiquitination,thatleadtochangesinchromatinstruc-
turewithconsequencesfor geneexpression.
13The “histone
code” hypothesis suggests that different types and com-
binations of modiﬁcations differentially alter chromatin
structure and transcriptional potential.
14 Acetylation of the
ε-amino group of lysine residues in the aminoterminal
tails of histones H3 and H4 is the best-characterized his-
tone modiﬁcation most consistently demonstrated to pro-
mote transcription. Histone acetylation is catalyzed by his-
tone acetyl transferases, which are recruited to acetylation
sites via requisite transcriptional cofactors, such as cyclic
AMP response element–binding protein and p300.
15 His-
tone deacetylation is associated with CpG methylation and
inactive chromatin structure. Four classes of HDACs cata-
lyze deacetylation, and they are themselves regulated by
posttranslational modiﬁcation.
16,17 Histone lysine methyl-
ation represents another important class of histone modiﬁ-
cation that alters gene expression, although the determi-
nants of expression (repression or promotion) are complex;
they depend on the position of the lysine and the extent of
its methylation and are not fully elucidated as yet. Similar
to histone acetylation, histone methylation is readily revers-
ible, with many known histone lysine methyltransferases
and demethylases that target speciﬁc lysines and speciﬁc
mono-, di-, or trimethylation states.
18-20 Figure 1 depicts the re-
lationships between DNA methylation and common histone
modiﬁcations in epigenetic regulation of gene expression.
Noncoding RNA
Long noncoding RNAs can silence genes, owing, in part,
to their recruitment of remodeling complexes, such as
the polycomb complex, that promote histone methylation.
These RNAs can also recruit RNA-binding proteins that
impair histone deacetylation or that inhibit transcription
factor binding to promoter regions.
21 Through these and
Figure 1. Chromatin structure and epigenetic tags. Nucleo-
somes are indicated as spheres, with sites of methylation and
acetylation on DNA and histone proteins listed in the key (re-
printed with permission from reference 1).
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for imprinting and X-chromosome inactivation and play
key roles in cardiac development.
22 Small inhibitory RNAs
and dicer-dependent microRNAs, as short noncoding
RNAs, have also been shown to play a role in transcrip-
tional suppression through several mechanisms, includ-
ing the recruitment of speciﬁc argonaute proteins to form
epigenetic remodeling complexes that promote histone
deacetylation, histone methylation, and DNA methyla-
tion.
23,24 The protein interaction world–interacting RNAs
(21–30 nt) are a single stranded subclass of these small
noncoding RNAs that have been shown to play a role in
maintaining the transgenerational inheritance of RNA-
induced epigenetic silencing.
25
RNA epigenetics
Posttranscriptional RNA modiﬁcations represent another
type of epigenetics, RNA epigenetics.
26 In particular, RNA
(tRNA, mRNA, and rRNA) can undergo methylation at a
variety of positions (Fig. 2) in the nucleotide base, as well as
at the 2 position of the ribose, and these methylation events
canmodulatefunction.
27TheRNAmethyltransferasescom-
prise four families and utilize S-adenosylmethionine as a
universal methyl donor. In addition, there is growing evi-
dence for RNA demethylases that may modulate gene ex-
pression. RNA methylation has different functional conse-
quences, including stabilization, enhanced function, and
quality control. In tRNA, for example, modiﬁcations are
found in certain regions of the tRNA and can contribute to
tertiary structure and the accuracy of tRNA recognition.
This ﬁeld of RNA epigenetics is in its infancy but promises
to offer yet another level of complex epigenetic regulation
ofgeneexpression.
EPIGENETIC CHANGES AND
CARDIOVASCULAR DISEASE
There is much discussion of late regarding so-called miss-
ing heritability in complex cardiovascular diseases, such
as hypertension and atherosclerosis. Some investigators
have posited that epigenetic changes may account for
some of this missing heritability. Sequence variation can,
for example, create or eliminate CpG sites that are meth-
ylation targets and, as a result, contribute to a change
in phenotype. For example, expression of the NDSUFB6
respiratory chain protein is decreased in type 2 diabetes
mellitus, and a single nucleotide polymorphism (SNP) in
the promoter region of this gene creates a CpG site with
methylation-dependent suppression of gene expression
demonstrated in patient muscle biopsy samples.
28 In addi-
tion, nutrition and environmental exposures during criti-
cal periods in life, such as in utero
29 or during periods of
famine,
30 can alter epigenetically the expression of genes
Figure 2. RNA methylation products. Common methylated bases found in mRNA, tRNA, and rRNA.
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sclerosis or hypertension. In part, this outcome may be a
consequence of dietary deﬁciency of folate or vitamin B12
or of choline (a betaine precursor necessary for folate-
independent methylation of homocysteine), essential for
methylation reactions that may epigenetically govern gene
expression.
One of the known risk factors for atherosclerosis and
vascular disease, homocysteine, may exert its actions via
an epigenetic mechanism also involving methylation reac-
tions (Fig. 3). Homocysteine is a key determinant of the
methylation cycle, in that it is methylated to methionine
(in a folate- and vitamin B12–dependent fashion), which
undergoes S-adenosylation to form S-adenosylmethionine
(SAM), which is the principal methyl donor for all meth-
ylation reactions in cells. The speciﬁcity of methylation de-
pends on the substrate speciﬁcity of any one of the more
than 100 methyltransferases in mammalian cells. Further-
more, SAM is converted to S-adenosylhomocysteine (SAH)
with methylation. The SAM-to-SAH ratio deﬁnes the meth-
ylation potential of a cell, and hyperhomocysteinemic states
decrease this ratio, leading to decreased methylation po-
tential. Several lines of evidence support the view that ho-
mocysteine can lead to global DNA hypomethylation
31,32
and can also suppress transcription of cyclin A in endothe-
lial cells. This gene-speciﬁc effect is exerted through de-
methylation of a CpG site in the core promoter, eliminat-
ing the binding of methyl CpG-binding protein 2, which,
in turn, limits HDAC binding and increases accumula-
tion of acetylated H3 and H4 histones to suppress gene
expression.
33 Thus, although DNA hypomethylation and
histone acetylation are associated with transcriptional per-
missive chromatin, the open conformation of chromatin
may also allow for augmented access by repressor pro-
teins, leading to transcriptional suppression. Similar epi-
genetic regulatory mechanisms have been reported to
account for changes in apoA-1 and apoA-IV in hyper-
homocysteinemia.
34 In contrast, other genes are upregu-
lated by homocysteine-induced DNA hypomethylation
of their promoters. One example is the homocysteine-
induced increase in p66shc expression in endothelial cells,
which correlates with promoter hypomethylation and con-
tributes to oxidant stress.
35
Epigenetic regulation of cardiovascular development
36
and cardiovascular stem cell biology
37 may be linked to
the cardiovascular disease propensity, as well. Epigenetic
regulation controls vascular smooth muscle phenotype in
health and disease.
38 Archer and colleagues
39 have also
shown that epigenetic attenuation of mitochondrial super-
oxide dismutase (SOD2) expression leads to pulmonary
artery smooth muscle cell proliferation and resistance to
apoptosis through a redox-dependent mechanism.
40 Re-
cent work suggests that increased HDAC activity contrib-
utes to the vascular pathobiology of pulmonary arterial
hypertension and that inhibition of histone deacetylation
is effective in attenuating disease progression and in re-
ducing established disease in a rat model of hypoxia-
induced pulmonary hypertension.
41 These studies tested a
class I HDAC inhibitor and a broader-spectrum drug that
inhibits class I, II, and IV HDAC, each of which reduced
pulmonary artery pressure, right ventricular hypertrophy,
and vascular muscularization to similar extents, with over-
lapping effects on histone acetylation and target gene ex-
pression. Similarly, other studies explored the ability of
other select HDAC inhibitors to preserve right ventricular
function and pulmonary blood ﬂow in hypoxia-induced
pulmonary hypertension in rats, reporting that class
I HDAC inhibitors improved right ventricular function by
lessening hypertrophy and reducing apoptotic and in-
ﬂammatory signaling.
42 In contrast, in a pulmonary artery
banding model of right ventricular pressure overload, use
of broad-spectrum HDAC inhibitors had a detrimental ef-
fect on right ventricular function, promoting dysfunction
and hypertrophy, possibly due to antiangiogenic effects of
these treatments.
43 This latter study reinforces the con-
cept that targeted HDAC inhibitors may lead to more ben-
eﬁcial treatment strategies and that a better understanding
of the underlying causative mechanisms for right heart
dysfunction is paramount. Similar approaches have been
used to regulate responses to heart failure in order to
mitigate remodeling responsible for left ventricular dys-
function. Various studies have shown a role for HDAC in
promoting maladaptive remodeling
44 and in HDAC inhib-
Figure 3. Methylation determinants and homocysteine metabolism.
AdoMet: S-adenosylmethionine; AdoHcy: S-adenosylhomocysteine
(reprintedwithpermissionfromreference1).
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models of cardiomyopathy.
45
Epigenetic regulation by miRNAs may also contribute
to cardiovascular disease processes. There is a growing list
of miRNAs that modulate cellular responses to hypoxia
and/or coordinately regulate pulmonary vascular changes
involved in the development of pulmonary arterial hyper-
tension.
46,47 For example, bioinformatics analysis sug-
gested that miR-21 may coordinately modify many targets
involved in the pathogenic pathways that contribute to
pulmonary hypertension.
48 In vivo, analysis shows that
this miRNA is upregulated in tissues from rodent models
and humans with pulmonary hypertension. In vivo, in-
hibition of miR-21 was found to lessen right ventricular
systolic pressure and pulmonary artery muscularization
in a mouse model of pulmonary hypertension but failed
to reduce hypoxia-induced right ventricular hypertrophy,
whereas inhibition of miR-17 had a greater effect on heart
and lung function in the hypoxia and monocrotaline mod-
els of pulmonary hypertension.
49 Similarly, other studies
implicate upregulation of miR-145 in smooth muscle pro-
liferation during hypoxia-induced pulmonary artery hyper-
tension, as inhibition of miR-145 signiﬁcantly lessened
vascular remodeling and right ventricular dysfunction in
the hypoxia model of pulmonary artery hypertension.
50
This study also reported that miR-145 is upregulated in
lungs of patients with idiopathic and heritable forms of
pulmonary artery hypertension, suggesting its potential
importance in human disease pathology. Other miRNAs,
including those that have protective actions, have simi-
larly been shown to regulate the vascular remodeling that
is characteristic of this disease. Thus, downregulation of
miR-204 in pulmonary hypertension was found to corre-
late with disease severity and smooth muscle cell prolifer-
ation, and delivery of synthetic miR-204 was capable of
mitigating disease in an animal model of pulmonary hy-
pertension.
51 Similarly, restoration of miR-424 and miR-
503 expression attenuated pulmonary hypertension in an
animal model, by mechanisms that may include their abil-
ity to regulate endothelial modulation of smooth muscle
cell proliferation.
52 Overall, these and other studies not
mentioned here suggest a growing importance of miRNAs
as critical regulators of complex cardiovascular phenotypes
and possible targets for therapeutic intervention.
CONCLUSIONS
Epigenetic regulation appears to be essential for cardio-
vascular development and differentiation. In addition, ab-
errant epigenetic mechanisms, brought about by environ-
mental determinants (homocysteine, vitamin deﬁciency
states) or on a variant genetic background (SNPs that al-
ter DNA methylation potential), can contribute to disease
pathogenesis and offer potential novel therapeutic targets.
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